Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tau PET imaging in neurodegenerative tauopathies—still a challenge
Antoine Leuzy, Konstantinos Chiotis, Laëtitia Lemoine, et al.
Molecular Psychiatry (2019) Vol. 24, Iss. 8, pp. 1112-1134
Open Access | Times Cited: 513

Showing 1-25 of 513 citing articles:

Alzheimer's disease
Philip Scheltens, Bart De Strooper, Miia Kivipelto, et al.
The Lancet (2021) Vol. 397, Iss. 10284, pp. 1577-1590
Open Access | Times Cited: 3091
Alzheimer's disease
José Arguedas López, Hector M. González, Gabriel C. Léger
Handbook of clinical neurology (2019), pp. 231-255
Closed Access | Times Cited: 634
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Eric Karran, Bart De Strooper
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 4, pp. 306-318
Open Access | Times Cited: 498
Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline
Juan Lantero Rodrı́guez, Thomas K. Karikari, Marc Suárez‐Calvet, et al.
Acta Neuropathologica (2020) Vol. 140, Iss. 3, pp. 267-278
Open Access | Times Cited: 280
Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease
Nicolai Franzmeier, Julia Neitzel, Anna Rubinski, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 262
The Microbiota–Gut–Brain Axis and Alzheimer’s Disease: Neuroinflammation Is to Blame?
Ashwinipriyadarshini Megur, Daiva Baltriukienė, Virginija Bukelskienė, et al.
Nutrients (2020) Vol. 13, Iss. 1, pp. 37-37
Open Access | Times Cited: 233
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease
Rik Ossenkoppele, Ruben Smith, Niklas Mattsson, et al.
JAMA Neurology (2021) Vol. 78, Iss. 8, pp. 961-961
Open Access | Times Cited: 228
Neuropathology of Alzheimer's Disease
Jorge Trejo‐Lopez, Anthony T. Yachnis, Stefan Prokop
Neurotherapeutics (2021) Vol. 19, Iss. 1, pp. 173-185
Open Access | Times Cited: 225
Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research
Christina M. Moloney, Val J. Lowe, Melissa E. Murray
Alzheimer s & Dementia (2021) Vol. 17, Iss. 9, pp. 1554-1574
Open Access | Times Cited: 197
Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other tauopathies
Heiko Kroth, Felix Oden, Jérôme Molette, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2019) Vol. 46, Iss. 10, pp. 2178-2189
Open Access | Times Cited: 190
Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade
George Crișan, Nastasia Sanda Moldovean-Cioroianu, Diana-Gabriela Timaru, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 5023-5023
Open Access | Times Cited: 184
Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders
Antoine Leuzy, Ruben Smith, Rik Ossenkoppele, et al.
JAMA Neurology (2020) Vol. 77, Iss. 8, pp. 955-955
Open Access | Times Cited: 180
APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease
Zonghua Li, Francis Shue, Na Zhao, et al.
Molecular Neurodegeneration (2020) Vol. 15, Iss. 1
Open Access | Times Cited: 180
Imaging biomarkers in neurodegeneration: current and future practices
Peter Young, Mar Estarellas, Emma M. Coomans, et al.
Alzheimer s Research & Therapy (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 165
An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders
Nicholas J. Ashton, Abdul Hye, Anto P. Rajkumar, et al.
Nature Reviews Neurology (2020) Vol. 16, Iss. 5, pp. 265-284
Open Access | Times Cited: 162
Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment
Avinash Chandra, Polytimi‐Eleni Valkimadi, Gennaro Pagano, et al.
Human Brain Mapping (2019) Vol. 40, Iss. 18, pp. 5424-5442
Open Access | Times Cited: 157
Tau PET imaging with 18F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study
André Mueller, Santiago Bullich, Olivier Barret, et al.
Journal of Nuclear Medicine (2019) Vol. 61, Iss. 6, pp. 911-919
Open Access | Times Cited: 157
From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy
Morvane Colin, Simon Dujardin, Susanna Schraen‐Maschke, et al.
Acta Neuropathologica (2019) Vol. 139, Iss. 1, pp. 3-25
Open Access | Times Cited: 157
Autophagy Assays for Biological Discovery and Therapeutic Development
Noboru Mizushima, Leon O. Murphy
Trends in Biochemical Sciences (2020) Vol. 45, Iss. 12, pp. 1080-1093
Open Access | Times Cited: 149
Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective
Geert Jan Biessels, Flavio Nobili, Charlotte E. Teunissen, et al.
The Lancet Neurology (2020) Vol. 19, Iss. 8, pp. 699-710
Closed Access | Times Cited: 145
“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies
Yuxing Xia, Stefan Prokop, Benoit I. Giasson
Molecular Neurodegeneration (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 144
Redefining the multidimensional clinical phenotypes of frontotemporal lobar degeneration syndromes
Alexander G. Murley, Ian Coyle‐Gilchrist, Matthew A Rouse, et al.
Brain (2020) Vol. 143, Iss. 5, pp. 1555-1571
Open Access | Times Cited: 140
Fluorine-containing pharmaceuticals approved by the FDA in 2020: Synthesis and biological activity
Yingjie Yu, Aiyao Liu, Gagan Dhawan, et al.
Chinese Chemical Letters (2021) Vol. 32, Iss. 11, pp. 3342-3354
Closed Access | Times Cited: 131
Regional Aβ-tau interactions promote onset and acceleration of Alzheimer’s disease tau spreading
Wha Jin Lee, Jesse A. Brown, Hye Ryun Kim, et al.
Neuron (2022) Vol. 110, Iss. 12, pp. 1932-1943.e5
Open Access | Times Cited: 126
Tau strains shape disease
Jaime Vaquer‐Alicea, Marc I. Diamond, Łukasz A. Joachimiak
Acta Neuropathologica (2021) Vol. 142, Iss. 1, pp. 57-71
Open Access | Times Cited: 115
Page 1 - Next Page

Scroll to top